RanjanaHiraAdvaniMD

Oncology • Stanford, CA

Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to view full profile

Dr. Advani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Advani's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1998
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1987 - 1991
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1989 - 1990
Grant Medical CollegeClass of 1983

Certifications & Licensure

CA State Medical License 1988 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Rituximab in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 1999 Jan 01
Completed
Phase 2
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma Start of enrollment: 2006 Jan 24
Terminated
Phase 2
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL Start of enrollment: 2009 Aug 01
Completed
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Start of enrollment: 2011 Jul 06
Completed
Phase 2
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Start of enrollment: 2013 May 24
Terminated
Phase 2
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Start of enrollment: 2011 May 01
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Mar 07
Suspended
Phase 1, Phase 2
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2015 Sep 28
Completed
Phase 1, Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Roles: Contact, Principal Investigator
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Start of enrollment: 2024 Feb 06
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

575 citations
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Martinez, Steven H Swerdlow
Blood. 2022-09-15
70 citations
Non-Hodgkin lymphoma of the breast.
Kristen N. Ganjoo, Ranjana H. Advani, M. Rajan Mariappan, Alex McMillan, Sandra J. Horning
Cancer. 2007-07-01
137 citations
Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
David W. Scott, Fong Chun Chan, Fangxin Hong, Sanja Rogic, King Tan
Journal of Clinical Oncology. 2013-02-20

Journal Articles

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Mark P Chao, Sonali M Smith, Ranjana Advani, Ian Flinn, Ravindra Majeti, Nancy L Bartlett, Leslie Popplewell, Justin Kline, Nilanjan Ghosh, Ann LaCasce, The New England Journal of Medicine

Abstracts/Posters

An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Ranjana Advani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Response to A+CHP by CD30 expression in the ECHELON-2 trial.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hodgkin Lymphoma: Beyond ABVD for Everyone
60th American Society of Hematology Annual Meeting - 12/1/2018
Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E0, the Bortezomib Ind...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cel...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evolving Treatment Paradigms of Early-Stage Hodgkin Lymphoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 res...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma®
Physicians' Education Resource, LLC, New York, New York - 2/15/2013
5th Annual T-cell Lymphoma Forum
Jonathan Wood & Associates, San Francisco, California - 1/24/2013
Join now to see all

Press Mentions

Non-Chemo Regimen Highly Active in R/R Hodgkin LymphomaAugust 23rd, 2021
International Prognostic Tool Predicts Outcomes in Angioimmunoblastic T-cell LymphomaJune 1st, 2021
CD47 Blocker Reverses Rituximab Resistance in LymphomaNovember 1st, 2018
Join now to see all